Nastech Pharmaceutical Company RSS Feed | Nachrichten - www.finanzen.net

Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced that having acquired shareholder approval, effective today the Company has changed its name to MDRNA, Inc. ("MDRNA�). MDRNA will leverage its scientific and intellectual ...

Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a Phase II clinical trial demonstrating that its ultra rapid acting intranasal insulin was both superior to usual therapy (oral anti-diabetic medicines and/or ...

Nastech Announces First Quarter 2008 Financial Results

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter ended March 31, 2008. Revenue for the three months ended March 31, 2008, was $1.3 million, compared to $5.0 million for the three ...

Nastech to Release First Quarter Financial Results and Host Webcast on Thursday, May 8, 2008

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial results will be released on Thursday, May 8, 2008, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). Management will then host a ...

Nastech Pharmaceutical Company Inc. Raises $7.93 Million in Registered Direct Offering

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has entered into definitive agreements with new and existing investors to raise gross proceeds of $7,932,500 though a registered direct offering. Under terms ...

Nastech Pharmaceutical Company Inc. Announces Appointment of Gunter Blobel, M.D., Ph.D., to its MDRNA, Inc. Scientific Advisory Board

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that Günter Blobel, M.D., Ph.D., has joined the Scientific Advisory Board of MDRNA, Inc., Nastech�s wholly-owned subsidiary for the development of RNAi technology ...

Nastech Pharmaceutical Company Inc. to Present RNAi Data

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that Narendra Vaish, Ph.D., MBA, Senior Research Scientist and Group Leader � RNAi Platform Technologies, will present a poster titled: RNAi Activity from siRNA Duplexes ...

Nastech Pharmaceutical Company Inc. Complies with Nasdaq Marketplace Rule 4350(b)(1)(B)

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK), in compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion that contains a going concern ...

Wall Street Media Presents a Video of Dr. Gordon Brandt, President of Nastech Pharmaceutical Company (NASDAQGM: NSTK)

Wall Street Media is presenting an exclusive highlight video from the presentation of Dr. Gordon Brandt, president of Nastech Pharmaceutical Company (NASDAQGM: NSTK) from the Invest Northwest(TM) Investor and CEO Forum on Tuesday, ...

Nastech Announces Fourth Quarter and Full Year 2007 Financial Results

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the fourth quarter and year ended December 31, 2007. Revenue for the three months ended December 31, 2007 was $6.4 million, compared ...